Clarus Therapeutics (CRXTQ) Stock Price, News & Analysis

Company Overview

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Key Stats

• Today's Range: $0.0010 to $0.0010
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $3.94
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRXTQ Stock Analysis - Frequently Asked Questions

How have CRXTQ shares performed this year?

Clarus Therapeutics' stock was trading at $0.0010 on January 1st, 2025. Since then, CRXTQ shares have increased by 0.0% and is now trading at $0.0010.
View the best growth stocks for 2025 here.

How were Clarus Therapeutics' earnings last quarter?

Clarus Therapeutics Holdings, Inc. (OTCMKTS:CRXTQ) released its quarterly earnings results on Thursday, November, 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.55. The business earned $4.29 million during the quarter, compared to analysts' expectations of $3.30 million.

How do I buy shares of Clarus Therapeutics?

Shares of CRXTQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/18/2021
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CRXTQ
• CUSIP: N/A
• CIK: 1817944
• Web: www.clarustherapeutics.com
• Phone: 847-562-4300
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A